DE60217653D1 - Verwendung von melatonin zur behandlung der mit konzentrationsschwäche einhergehenden hyperaktivität - Google Patents

Verwendung von melatonin zur behandlung der mit konzentrationsschwäche einhergehenden hyperaktivität

Info

Publication number
DE60217653D1
DE60217653D1 DE60217653T DE60217653T DE60217653D1 DE 60217653 D1 DE60217653 D1 DE 60217653D1 DE 60217653 T DE60217653 T DE 60217653T DE 60217653 T DE60217653 T DE 60217653T DE 60217653 D1 DE60217653 D1 DE 60217653D1
Authority
DE
Germany
Prior art keywords
melatonin
hyperactivity
weakness
concentrated
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60217653T
Other languages
English (en)
Other versions
DE60217653T2 (de
Inventor
Johannes Kruisinga
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
POOGER PROPERTIES Ltd
Original Assignee
POOGER PROPERTIES Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by POOGER PROPERTIES Ltd filed Critical POOGER PROPERTIES Ltd
Publication of DE60217653D1 publication Critical patent/DE60217653D1/de
Application granted granted Critical
Publication of DE60217653T2 publication Critical patent/DE60217653T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DE60217653T 2001-03-22 2002-03-22 Verwendung von Melatonin zur Behandlung von Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom Expired - Lifetime DE60217653T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01201094 2001-03-22
EP01201094 2001-03-22
PCT/EP2002/003317 WO2002076452A1 (en) 2001-03-22 2002-03-22 Use of melationin in the manufacture of a medicament for treating attention deficit hyperactive disorder

Publications (2)

Publication Number Publication Date
DE60217653D1 true DE60217653D1 (de) 2007-03-08
DE60217653T2 DE60217653T2 (de) 2007-10-18

Family

ID=8180055

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60217653T Expired - Lifetime DE60217653T2 (de) 2001-03-22 2002-03-22 Verwendung von Melatonin zur Behandlung von Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom

Country Status (7)

Country Link
US (1) US20040097577A1 (de)
EP (1) EP1370259B1 (de)
JP (1) JP4620329B2 (de)
CA (1) CA2357114C (de)
DE (1) DE60217653T2 (de)
ES (1) ES2280510T3 (de)
WO (1) WO2002076452A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003270292A1 (en) * 2002-09-26 2004-04-19 Pooger Properties Limited Combined use of methylphenidate and melatonin for treating attention-deficit hyperactive disorder
ES2209649B1 (es) * 2002-12-09 2005-03-16 Carlos Arana Molina (Titular Al 25%) Utilizacion de la melatonina para la higiene bucodental para uso humano y veterinario como producto activo.
CA2523399A1 (en) * 2005-10-14 2007-04-14 Institut Pasteur Genetic variations associated with psychiatric disorders
CN101754753A (zh) * 2007-05-24 2010-06-23 纽约市哥伦比亚大学托管会 褪黑素的持久释放配方
EP2248808B1 (de) * 2008-01-31 2014-07-16 Takeda Pharmaceutical Company Limited Prophylaktischer oder therapeutischer wirkstoff gegen aufmerksamkeitsdefizite und hyperaktivität
ITMI20112042A1 (it) * 2011-11-10 2013-05-11 Eratech S R L Polvere da ricostituire prima dell'uso comprendente melatonina e preparazione iniettabile ottenibile da tale polvere.
UA107653U (uk) * 2012-10-01 2016-06-24 Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5449683A (en) * 1992-10-01 1995-09-12 Massachussetts Institute Of Technology Methods of inducing sleep using melatonin
US5654325A (en) * 1993-11-18 1997-08-05 Eli Lilly And Company Melatonin derivatives for use in treating sleep disorders
US5942536A (en) * 1995-10-10 1999-08-24 Eli Lilly And Company N- 2-substituted-3-(2-aminoethyl)-1H-indol-5-YL!-Amides: new 5-HT1F agonists

Also Published As

Publication number Publication date
EP1370259B1 (de) 2007-01-17
DE60217653T2 (de) 2007-10-18
US20040097577A1 (en) 2004-05-20
WO2002076452A1 (en) 2002-10-03
ES2280510T3 (es) 2007-09-16
JP2004524344A (ja) 2004-08-12
EP1370259A1 (de) 2003-12-17
CA2357114A1 (en) 2002-09-22
CA2357114C (en) 2010-06-29
JP4620329B2 (ja) 2011-01-26

Similar Documents

Publication Publication Date Title
DE60234760D1 (de) Phenylindole zur behandlung von hiv
ATE275145T1 (de) Chinazolinderivate zur behandlung von tumoren
DE60325770D1 (de) Verwendung von rimexolon zur behandlung von augentrockenheit
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
ATE358669T1 (de) Pyrazolderivate zur behandlung von hiv
DE60335293D1 (de) Pyrrolopyridazin-verbindungen und verwendungsverfahren dafür zur behandlung von proliferativen erkrankungen
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE331512T1 (de) Verwendung azetidinone-substituierter verbindungen zur behandlung der sitosterolhämie
DE60322451D1 (de) 4-Tetrazolyl-4-Phenylpiperidinderivate zur Schmerzbehandlung
DE50212701D1 (de) Bestrahlungsanordnung zur behandlung von akne und aknenarben
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60229959D1 (de) Kombinationstherapie zur behandlung von krebs
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE60208221D1 (de) Heterozyklische verbindungen zur behandlung von harnwegserkrankungen
DE502004010131D1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
ATE279386T1 (de) Retinoide zur behandlung von emphysem
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
DE602004022035D1 (de) Verwendung von pthalide derivativen zur behandlung
DE60238765D1 (de) Carbamatverbindungen zur behandlung von schmerz
DE60214355D1 (de) Exemestan zur behandlung von hormonabhängigen störungen
DE60217653D1 (de) Verwendung von melatonin zur behandlung der mit konzentrationsschwäche einhergehenden hyperaktivität
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
DE60223718D1 (de) Verwendung von norepinephrin wiederaufnahmehemmern zur behandlung von kognitiven störungen
ATE273276T1 (de) Cyclobutendion-derivate zur behandlung von artherosclerose

Legal Events

Date Code Title Description
8364 No opposition during term of opposition